Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study

Table 4

Capability and feasibility of each metabolite in distinguishing DKD from non-DKD based on ROC analysis.

Models	AUC	95% CI	SE
Hexadecanoic Acid (C16:0)	0.8	0.66, 0.93	0.07
Linolelaidic Acid (C18:2N6T)	0.84	0.72, 0.95	0.06
Linoleic Acid (C18:2N6C)	0.81	0.68, 0.94	0.07
Trans-4-Hydroxy-L-Proline	0.74	0.58, 0.89	0.08
6-Aminocaproic Acid	0.79	0.65, 0.93	0.07
L-Dihydroorotic Acid	0.85	0.73, 0.98	0.06
6-Methylmercaptopurine	0.73	0.58, 0.88	0.08
Piperidine	0.75	0.60, 0.90	0.08
Azoxystrobin Acid	0.82	0.69, 0.95	0.07
Lysopc 20:4	0.75	0.60, 0.90	0.08
Cuminaldehyde	0.76	0.61, 0.90	0.07
Combine	0.93	0.85, 1.00	0.04

AUC: area under the curve.